Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.